By Marie Rosenthal
The FDA approved galcanezumab-gnlm (Emgality, Eli Lilly) to prevent migraine in adults.
Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene–related peptide and blocks its binding to the receptor preventing migraines. Galcanezumab-gnlm, which should be available soon, will be given as a once-monthly, self-administered subcutaneous injection.
The efficacy and safety of galcanezumab-gnlm were demonstrated in two phase 3 clinical